Navigation Links
Landmark study opens door to new cancer, aging treatments
Date:8/31/2008

ctive in cells that multiply frequently, such as embryonic stem cells, but is switched off almost entirely in normal adult cells to prevent the dangers of runaway cell proliferation.

Cancer cells, however, often regain the ability to activate telomerase, which has been implicated in 90 percent of human tumors. The enzyme permits cells to replicate indefinitely and achieve the cellular "immortality" that is the hallmark of cancer. Deactivating telomerase would stop tumor growth.

In addition to its role in cancer, telomerase holds significant implications for the development of therapies to combat aging and other age-related diseases. Finding ways to activate telomerase under controlled conditions and allow some cells to begin dividing again could result in healthier, younger-looking tissue that lives longer.

An elusive enzyme

Telomerase is a complex structure made up of multiple protein domains and a stretch of RNA, which contains the template the enzyme uses to synthesize telomeres.

Last year, Skordalakes and his team solved the structure of a key segment of the moleculethe so-called TRBD domain, where RNA binding occurs. However, the complexity of telomerase has proved a roadblock to determining the enzyme's overall architecturea goal pursued by researchers worldwide for more than 15 years.

To perform the necessary studies, scientists first must gather large quantities of the enzyme in a specific conformation. Because the complex structure of telomerase most likely allows it to change configuration, that process has been challenging, Skordalakes says.

To find sufficient quantities of the enzyme for the study, Skordalakes and his team looked beyond commonly relied-on sources such as humans and yeast. By screening a wide variety of organisms, including protozoa and insects, they discovered that a gene from the red flour beetle could produce telomerase in copious amounts, and a stable form.


'/>"/>
Contact: Abbey J. Porter
aporter@wistar.org
215-898-3943
The Wistar Institute
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Childrens national co-leads nationwide study of landmark sickle cell treatment
2. Landmark studies assess risk of exposure to elevated levels of EMS confirm clear toxicity threshold
3. SAGE and Hindawi announce landmark open access agreement
4. Safeway Inc. and PCF to fund landmark prostate cancer research collaboration
5. Study shows more genes are controlled by biological clocks
6. Armored fish study helps strengthen Darwins natural selection theory
7. Study says eyes evolved for X-Ray vision
8. Study of islands reveals surprising extinction results
9. Study points to potential new use for Viagra
10. Unique study shows oil, gas seismic work not affecting Gulf sperm whales
11. ETH Zurich study on salmonella self-destruction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2014)... December 9, 2014   ... Platform   Jifflenow, ... scheduling solutions for business-to-business (B2B) events, today announced ... in mobile near-field communication (NFC), Bluetooth low energy ... (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate ...
(Date:12/4/2014)... , Dec. 3, 2014  Crossmatch™, a ... announced that its DigitalPersona ® Pro Enterprise ... have been deployed throughout First Bank branch locations ... South Carolina and Virginia. First Bank, ... Southern Pines, North Carolina , selected ...
(Date:11/21/2014)... November 18, 2014 According to ... by Systems (Video, RFID, Access Control, Intrusion Detection, Parking ... Banks, Government), Component Service Geography - Global Forecasts to ... is projected to be around $25 Billion in 2014 ... growing at a CAGR of 8.69%. Browse ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... with fossils led to Natural Sciences and Engineering Research Council ... the oldest known reptile that stands on two legs. ... years of research excellence by joining the ranks of the ... will induct him as a fellow during its annual conference, ...
... pinpointed a natural ingredient of human blood that effectively ... from infecting immune cells and multiplying. The virus blocker ... to full-blown AIDS and—because it works in a different ... of another class of drugs in the fight against ...
... the influenza virus that killed 50 million people in 1918, ... to how the virus killed so quickly and efficiently. , ... a team led by University of Wisconsin-Madison virologist Yoshihiro Kawaoka ... influenza strain - unleashes an immune response that destroys the ...
Cached Biology News:Old dinosaur research leads to new honor 2Discovery of an HIV inhibitor in human blood points to new drug class 2Discovery of an HIV inhibitor in human blood points to new drug class 3Study uncovers a lethal secret of 1918 influenza virus 2Study uncovers a lethal secret of 1918 influenza virus 3
(Date:12/24/2014)... AUSTIN, Texas , Dec. 24, 2014 /PRNewswire/ ... company focused on gynecologic disease, announced today that ... with investors including Oracle Investment Management, Jack ... Vermillion directors. Total proceeds were $10.5 million, before ... working capital and general corporate purposes. ...
(Date:12/24/2014)... 2014 Earlier this year in a ... director of the Adult Stem Cell Technology Center, LLC ... and under appreciated unique property of adult tissue stem ... Cells: Misunderstood in the Past, Important for the Future,” ... He gave the address at the 4th World ...
(Date:12/24/2014)... Texas (PRWEB) December 23, 2014 ... methyl mercaptan such as its definition, classification, ... presents product specification, manufacturing process, and product ... technology and applications. The analysis also covers ... marketing channels, industry development trend and proposals. ...
(Date:12/24/2014)... , Dec. 23, 2014 China Biologic ... "Company"), a leading fully integrated plasma-based biopharmaceutical company ... that its majority-owned subsidiary, Shandong Taibang Biological Products ... certification from the China Food and Drug Administration ... facility. As previously disclosed in the Company,s public ...
Breaking Biology Technology:Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3
... Primary ... SAN DIEGO, May 27 Favrille, Inc. (Nasdaq:,FVRL) ... trial,of Specifid(TM) following Rituxan(R) in patients with follicular B-cell,non-Hodgkin,s ... Analysis of time to progression (TTP), the primary endpoint ...
... May 26 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE:,WX), ... research,and development outsourcing company with operations in ... that it has appointed Dr. Peng Wang ... http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ), Prior to ...
... SAN DIEGO, May 23 Amylin Pharmaceuticals,Inc. (Nasdaq: ... Stockholders on,Friday, May 30, 2008 at 11:00 a.m. PT ... the Annual Meeting, Daniel M.,Bradbury, President and Chief Executive ... The live presentation will be Web cast, and ...
Cached Biology Technology:Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with Follicular B-Cell Non-Hodgkin's Lymphoma 2Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with Follicular B-Cell Non-Hodgkin's Lymphoma 3WuXi PharmaTech (NYSE: WX) Appoints Dr. Peng Wang as VP of Discovery Biology 2
... The Z-Competent E. coli Transformation Buffer ... of competent E. coli cells for simple ... method completely eliminates the requirement for heat ... transformation can be performed by adding DNA ...
Request Info...
Buffer used for mitocapture assays....
... automated perfusion system. For real-time or ... biophysics, electrochemistry, or general liquid-handling research ... millisecond accuracy Run experiments automatically ... accuracy and flexibility Turnkey perfusion ...
Biology Products: